CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

As the largest MA plan sellers, UnitedHealth, Humana and CVS Health collectively account for nearly 60% of the market.

Dividend stocks are great for various reasons, and it's even better to invest in them while they are going through a rough patch, provided there are good reasons to believe they will recover. This des...

The CVS Health stock price rebounded to $48 on Monday, up 10% from its lowest in December. This rebound continued after the strong Walgreens Boots Alliance earnings, which pushed the stock up almost 5...

How would you like to get paid to sit back and watch a stock you own take off? That's a scenario most investors would love.

Despite significant headwinds and a 43% stock decline, CVS Health's 5.8% dividend yield remains attractive, with a well-covered payout ratio of 55.9%. CVS faces strong competition from Amazon, Walmart...

CVS Health (CVS 0.50%) is a stock that's been struggling badly for multiple years and is coming off a brutal performance in 2024, when its shares nose-dived by 43%.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

CVS Health has been named as a Top 25 dividend stock, according the most recent Dividend Channel ''DividendRank'' report. The report noted that among the coverage universe, CVS shares displayed both a...

CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the resumption of member redeterminations.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.

Not all REITs are equal. The asset quality can differ greatly from one REIT to another. I highlight a good example of that.

Legislation slowly wending its way through states and in Washington could mean increased payments to drugstore chains like CVS Health, Walgreens, Walmart and independent pharmacies across the country.

In the latest trading session, CVS Health (CVS) closed at $44.36, marking a +1.32% move from the previous day.

TD Cowen keeps a Buy rating and $80 price target on CVS. The firm says the DOJ complaint relating to opioid prescriptions is incremental to the 2022 settlement with state and local governments for $5B...

Investors feel optimistic about CVS Health's 2025 roadmap. Yet, poor macroeconomic conditions are concerning.

CVS Health Corp (NYSE:CVS) has been accused by the US Department of Justice of violating the Controlled Substances Act (CSA) and the False Claims Act (FCA). A lawsuit filed in Rhode Island claims CVS ...